Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levilimab (Primary)
  • Indications COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms CORONA
  • Sponsors Biocad

    • Most Recent Events

    • 01 Dec 2021 Primary endpoint (Proportion of patients with sustained clinical recovery) has been met, according to the results published in the Inflammation Research.
    • 01 Dec 2021 Results assessing the efficacy and safety of LVL in subjects with severe COVID-19, published in the Inflammation Research.
    • 05 Jun 2021 Results assessing pharmacodynamic effect by changes in the serum concentrations of inflammatory markers Erythrocyte sedimentation rate, C-reactive protein, and IL-6 in patients treated with Levilimab or placebo, presented at the 22nd Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top